Pharmaceuticals news FT.com

Novartis agrees $3bn deal to buy heart drug biotech from Blackstone

Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019

Feb 11, 2025 - 12:00
 0
Novartis agrees $3bn deal to buy heart drug biotech from Blackstone
Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019
Read More

Tags:

Previous Article

Chorley Group introduces EV-specific marketing to drive leads

Next Article

Soaring high levels of precision now possible with new 3DMakerpro Eagle 3D scann...

Related Posts

Activist fund takes aim at one of Japan’s biggest pharma groups

Activist fund takes aim at one of Japan’s biggest pharm...

Feb 12, 2025  0

Ex-DeepMind scientist launches AI drug discovery venture

Ex-DeepMind scientist launches AI drug discovery venture

Feb 13, 2025  0

Merck shares sink 11% after vaccine shipments to China halted

Merck shares sink 11% after vaccine shipments to China ...

Feb 9, 2025  0